Document Detail

Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure.
MedLine Citation:
PMID:  25224934     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: As complex disease, heart failure is associated with various pathophysiological and biochemical disorders. No single biomarker is able to display all these characteristics. Therefore, we evaluated a multimarker panel together with the biochemical gold-standard NT-proBNP. Part of the panel are markers for angiogenesis (Endostatin, IBP-4, IBP-7, sFlt-1 as antiangiogenetic factors and PLGF as angiogenectic factor), myocyte stress (GDF-15), extracellular matrix remodelling (galectin-3, mimecan and TIMP-1), inflammation (galectin-3) and myocyte injury (hs-TnT).
METHODS: All markers (Roche Diagnostics, Penzberg, Germany) were assessed in a cohort of 149 patients with chronic heart failure and 84 healthy controls.
RESULTS: All markers were positively correlated with ln NT-proBNP (each p < 0.05). Furthermore, they were significantly elevated in patients with chronic heart failure (each p < 0.05). All markers increased significantly with severity of LV dysfunction and severity of New York Heart Association class (each p < 0.05), except for PLGF and Mimecan (each p = NS). With the exception of endostatin, mimecan and PLGF, all other markers were further significant predictors for all-cause mortality in a 3-year follow-up. In a multimarker approach of the five biomarkers with the best performance (NT-proBNP, hs-TnT, TIMP-1, GDF-15 and IBP-4), the event rate was superior to NT-proBNP alone and increased significantly and progressively with the number of elevated biomarkers.
CONCLUSION: All emerging markers increased stepwise with the severity of symptoms and LV dysfunction and offer important prognostic information in chronic heart failure, except for PLGF and mimecan. Five biomarkers with different pathophysiological background incorporated additive prognostic value in heart failure. Prognostication in heart failure may be further improved through a multimarker approach.
Carsten G Jungbauer; Julia Riedlinger; Dirk Block; Stefan Stadler; Christoph Birner; Monika Buesing; Wolfgang König; Günter Riegger; Lars Maier; Andreas Luchner
Related Documents :
10994734 - The role of fatty acids in cardiac imaging.
21323734 - Massive cardiac fibroma.
18450834 - Cardiac stimulation with high voltage discharge from stun guns.
25354034 - St elevation myocardial infarction: recent advances and updates.
570054 - Myocardial biopsy in diagnosis of endomyocardiopathy in patient with electro- and vecto...
18852584 - Appraising the pathophysiologic impact of coronary collaterals as measured by fractiona...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Biomarkers in medicine     Volume:  8     ISSN:  1752-0371     ISO Abbreviation:  Biomark Med     Publication Date:  2014 Jul 
Date Detail:
Created Date:  2014-09-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101312535     Medline TA:  Biomark Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  777-89     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The mechanism and regioselectivity of gold(i) or platinum(ii) catalyzed intramolecular hydroarylatio...
Next Document:  The ease of use and reproducibility of the Alere™ Heart Check System: a comparison of patient and he...